Related Experiment Video
Updated: Apr 17, 2026
08:14
A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
8.7K
Targeting PCSK9 for therapeutic gains.
Michael D Shapiro1, Sergio Fazio, Hagai Tavori
1The Knight Cardiovascular Institute, Center for Preventive Cardiology, Oregon Health and Science University, 3181 S.W. Sam Jackson Park Road, Portland, OR, USA.
Current Atherosclerosis Reports
|February 26, 2015
Summary
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition shows therapeutic potential for cholesterol management. This review highlights recent clinical trial data and future research directions for PCSK9 antibodies.
Area of Science:
- Biochemistry
- Cardiovascular Medicine
- Pharmacology
Background:
- Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a plasma protein linked to hypercholesterolemia.
- PCSK9 plays a crucial role in cholesterol metabolism.
- Recent discoveries have illuminated PCSK9's unique physiology.
Purpose of the Study:
- To review the latest clinical trial data on PCSK9 inhibition.
- To highlight the clinical significance of ongoing PCSK9 studies.
- To suggest future research avenues based on PCSK9 physiology.
Main Methods:
- Review of phase II/III clinical trials involving PCSK9 inhibition.
- Analysis of data from leading PCSK9 antibodies.
- Synthesis of recent basic science discoveries on PCSK9.
Main Results:
- Summarizes recent phase II/III clinical trial data for PCSK9 inhibitors.
- Highlights the clinical significance and impact of PCSK9 antagonism on cholesterol metabolism.
- Presents an overview of the therapeutic potential of PCSK9 antibodies.
Conclusions:
- PCSK9 inhibition represents a significant therapeutic strategy for managing cholesterol levels.
- Ongoing research continues to uncover the complexities of PCSK9's role in lipid metabolism.
- Future investigations are warranted to further elucidate PCSK9 physiology and optimize therapeutic applications.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
95
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
95
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
667
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
667
01:26Atherosclerosis III: Management
613
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
613
01:27Transducer Mechanism: Enzyme-Linked Receptors
5.1K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
5.1K
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
132
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
132
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K